Prediction of Outcomes in Mild Cognitive Impairment by Using 18F-FDG-PET: A Multicenter Study

Area of Science:

• Neurology
• Nuclear Medicine
• Biomarker Research

Background:

• 18F-FDG-PET is a recognized biomarker for neuronal injury per NIA-AA criteria.
• Mild cognitive impairment (MCI) is a prodromal stage for dementia, including Alzheimer's disease (AD).

Purpose of the Study:

• To evaluate the predictive value of 18F-FDG-PET for Alzheimer's disease (AD) development in patients with mild cognitive impairment (MCI).
• To compare visual interpretation with an automated PET score for predicting MCI to AD conversion.

Main Methods:

• A multicenter prospective cohort study involving 114 MCI patients.
• Clinical, neuropsychological, MRI, and 18F-FDG-PET assessments at baseline.
• 3-year follow-up to evaluate dementia progression, with visual and automated PET analysis.

Main Results:

• 47% of MCI patients progressed to probable AD within 3 years.
• The automated PET score achieved 83% diagnostic accuracy at 2 years, outperforming visual interpretation.
• The PET score was the most significant predictor of MCI to AD conversion.

Conclusions:

• The PET score is a highly significant predictor for conversion from MCI to AD.
• The PET score demonstrates promising diagnostic performance, particularly for rapid converters within 2 years.